Molecular Tumor Board for advanced cancer patients
Molecular Tumor Board at the Center for Personalized Medicine Tübingen: a Prospective Observational Study
University Hospital Tuebingen · NCT03503149
This study looks at how well the advice from a special team of doctors helps advanced cancer patients live longer and feel better in their everyday lives.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | University Hospital Tuebingen (other) |
| Locations | 1 site (Tübingen, Baden-Wurttemberg) |
| Trial ID | NCT03503149 on ClinicalTrials.gov |
What this trial studies
This study involves the Molecular Tumor Board at the Center for Personalized Medicine in Tübingen, which aims to document patients referred for molecular tumor profiling in routine clinical care. It focuses on tracking clinical outcomes such as progression-free survival and overall survival, as well as patient-reported outcomes. The study also evaluates how well the recommendations from the tumor board are followed in clinical practice. There are no interventions involved, as it is observational in nature.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with advanced cancer who have been referred to the Molecular Tumor Board by their treating physician.
Not a fit: Patients who do not have cancer or those who do not meet the referral criteria for the Molecular Tumor Board will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance personalized treatment strategies for advanced cancer patients based on molecular profiling.
How similar studies have performed: Other studies utilizing molecular tumor boards have shown promise in improving treatment outcomes, indicating that this approach is supported by prior success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
* Given informed consent ("broad consent" of the University Hospital Tübingen)
* ≥ 18 years of age
* Clinical indication for a referral to Molecular Tumor Board by the treating physician
Exclusion Criteria:
* The MTB assists the referring physician with the interpretation and the use of tumor molecular profiling data for deciding on a therapeutic strategy. Therefore, this board is confined to cancer patients and cannot provide any service for non-cancer patients
Where this trial is running
Tübingen, Baden-Wurttemberg
- University Hospital Tübingen — Tübingen, Baden-Wurttemberg, Germany (RECRUITING)
Study contacts
- Principal investigator: Ghazaleh Tabatabai, Prof — University Hospital Tübingen
- Study coordinator: Ghazaleh Tabatabai, Prof
- Email: ghazaleh.tabatabai@med.uni-tuebingen.de
- Phone: 0049707129
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Advanced Cancer